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Abstract.
BACKGROUND: Alzheimer’s disease (AD) is the most common neurodegenerative disease and a major source of morbidity
and mortality. Currently, no therapy nor drug can cure or modify AD progression, but recent studies suggest that nutritional
compounds in certain foods can delay or prevent the onset of AD. Diets with high antioxidants is one of the examples
which is believed to influence AD pathogenesis through direct effect on amyloid beta levels. Compared to other fruits and
vegetables, goji berry (GB) has high levels of polyphenolic substances with antioxidant activities which have shown some
positive effects on cognitive function while its mechanism on neuroprotection is yet to be explored. We investigated whether
GB would decrease the quantity of amyloid beta in cell culture model of AD.
OBJECTIVE: To assess the protective effects of GB against amyloid beta toxicity in M17 cells using different techniques.
METHODS: Goji berry powder (GBP) at different concentrations was treated with 20 M amyloid beta-induced
neuronal cells. MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium),
bicinchoninic acid (BCA) assay, Western blot analysis, enzyme-linked immunosorbent assay (ELISA) and atomic force
microscopy (AFM) were performed to identify how GB affected amyloid beta.
RESULTS: MTS assay indicated that GBP significantly increased cell viability up to 105% when GBP was at 1.2 g/mL.
Western blot showed significant reduction of amyloid beta up to 20% in cells treated with 1.5 g/mL GBP. GBP at 1.5 g/mL
was the most effective concentration with 17% reduction of amyloid beta in amyloid beta-induced neuronal cells compared
to control (amyloid beta only) based on ELISA results. AFM images further confirmed increasing GBP concentration led to
decreased aggregation of amyloid beta.
CONCLUSION: GB can be a promising anti-aging agent and warrants further investigating due to its effect on reduction of
amyloid beta toxicity.
Keywords: Goji berry, Alzheimer’s disease, amyloid beta, cell viability, BCA, Western blot, ELISA, AFM
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1. Introduction
Alzheimer’s disease (AD) is a progressive neu-
rodegenerative disease caused by nerve cell death
resulting in loss of short-term and long-term mem-
ory, thinking and language skills, and behavioural
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of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).
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changes. In 2016, the total cost of dementia in Aus-
tralia was 14.25 billion AUD and it is estimated to
reach 36.8 billion AUD which is more than two-fold
increase in 2036. AD is characterised by the forma-
tion of extracellular senile plaques (amyloid beta) and
intracellular neurofibrillary tangles in brain [1]. The
production and deposition of the amyloid beta peptide
in the aging brain are the main pathology of AD. The
concentration of amyloid beta in an AD patient brain
is significantly higher than that of a normal health
person [2]. Amyloid beta causes neuronal loss and
the clinical manifestation of AD is correlated with
the degree of neuronal loss in brain [3]. Thus, it is
believed that therapeutic strategies focusing on the
modulation of amyloid beta toxicity is important to
avoid the development and progression of AD. There-
fore, it is essential to identify a drug that effectively
reduce the loss of neurons due to amyloid beta toxic-
ity to prevent the decline in cognitive abilities in AD.
Currently, only neurotransmitter modulator is avail-
able as an approved drug against AD. Research has
also indicated that food compounds with high levels
of antioxidants is one of the preventative options for
AD that has attracted a lot of attention. These com-
pounds can attenuate the progression of the disease by
reducing oxidative stress, neuronal death and inflam-
mation due to the presence of antioxidants [4]. The
use of GB as an antioxidant has shown promising
neuroprotection. However, its therapeutic potential
towards the reduction of amyloid toxicity has not
been evaluated.
GB or wolfberry is the fruit of Lycium barbarum
and Lycium chinense. It is a deciduous fruit of 1–2 cm
in diameter and produced by a perennial shrub.
Usually, GB grows up to 1–3 meters in height and pro-
duces ellipsoid, bright orange-red berries. The taste
of fresh GB is sweet and sour. GB contains a wide
range of nutrients and bioactive compounds includ-
ing polysaccharides (5–8% in dried GB), carotenoids
(0.3–0.5% in dried GB), amino acids, betaine, cere-
broside, beta-sitosterol, p-coumaric acid, and various
vitamins (B1, B2, B6 and E) [5–7]. These com-
pounds have antioxidation, anti-inflammatory, and
anti-neoplastic properties which have been used for
the treatment of various blood circulation disorders
and diabetes [8]. GB has demonstrated its health
benefits on improvement of metabolism, vision,
blood circulation, kidney, liver and lungs function
[5, 9, 10].
Recent work identified that GB could enhance cog-
nitive function and reduce the risk factors related to
AD via prevention of brain oxidative mitochondrial
damage due to its polysaccharides including arabi-
nose, rhamnose, mannose and galactose [5, 11]. For
example, GB contains betaine which has a strong
potential to scavenge free radicals and is important
to reduce the oxidative stress in neuronal cells [12].
Oxidative stress causes more production of amy-
loid beta in the brain [12]. GB also can activate T
cells, B cells, macrophages, NK cells and other major
immune cells that are important to maintain cellular
immune function and humoral immune function [13].
As a result, GB has shown to reduce the risk factors
related to AD such as oxidative stress through initi-
ating immune cells [10, 14]. The aim of our study
was to identify the effect of GB on the physiological
levels of amyloid beta which determines the rate of
neuronal death under in vitro conditions.
2. Materials and methods
Goji berry powder (GBP) was purchased from
Bozhou Baofeng Biotech Co., Ltd. As advised by the
manufacturer, GB was convective dried in 3 stages.
Firstly, fresh GB was dried under 45◦C for 36 h. Then
further dried at 50◦C for 48 h and 55◦C for 24 h. After
drying, GB was ground into GBP at 200 mesh.
2.1. Degradation or clearance of amyloid beta
2.1.1. Preparation of amyloid beta oligomers
Amyloid beta oligomer solution was prepared
as per method described by Stine, Jungbauer [15].
The 1 mM amyloid beta solution was prepared
by adding 2.217 mL hexafluoroisopropanol (HFIP)
directly to the vial containing 10 mg amyloid beta
42 lyophilized powder (W. M. Keck Laboratory, US)
through the rubber septum using a 2.5 mL glass
Hamilton syringe with a Teflon plunger and sharp
(not blunt end) needle. Once the amyloid beta pep-
tides were completely dissolved, septum was pierced
with a syringe needle to release the vacuum. The
amyloid beta-HFIP solution was incubated at room
temperature for 30 mins. Then the glass vial was
decapped, and the rubber septum was removed (Note:
HFIP should not be in contact with the septum).
The amyloid beta-HFIP solution was aliquoted by
Eppendorf positive-displacement pipetting 100 L
(containing 0.45 mg amyloid beta 42) into 1.7 mL
microcentrifuge tubes using micropipette. The amy-
loid beta-HFIP solution was allowed to evaporate
in the open tubes overnight in a fume hood. To
remove any remaining traces of HFIP and moisture,
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tubes were transferred to a SpeedVac (PD131DDA,
Thermo Scientific, US) and dried for 1 h without heat-
ing. A thin and clear film of peptides was observed
at the bottom of the tubes once it was removed from
the SpeedVac. These tubes with dried peptide films
were stored over desiccant in a glass jar at –20◦C in
a freezer. Prior to use, amyloid beta peptide film was
taken from the freezer and allowed to return to room
temperature.
The 5 mM amyloid beta dimethyl sulfoxide
(DMSO) stock was prepared by adding 20 L fresh
dry DMSO into a tube with 0.451 mg amyloid beta
42 peptide (2 L to 0.045 mg amyloid beta 42). A
complete resuspension of peptide film in which the
amyloid beta DMSO stock was clean and cloudless
was achieved by pipetting thoroughly and scraping
down the sides of the tube. Then vortexed (vor-
texer: PV-1, BIOLAB, US) the tube vigorously for
30 sec and used a microcentrifuge tube to collect
the solution, followed by sonicating for 10 mins in
a water-bath sonicator (ultrasonic cleaner: 250HD,
SONICLEAN, Japan). This was used as the starting
material for oligomeric amyloid beta preparation.
The 100 M amyloid beta was prepared by pipet-
ting 2 L of 5 mM amyloid beta DMSO solution and
98 L cold phenol-free F12 solution to a new tube.
To prepare oligomers, solution was vortexed for 15
sec (vortexer: PV-1, BIOLAB, US) and incubated for
24 h at 4◦C in a cold room.
2.1.2. Culturing of cells
Culturing human neuroblastoma BE(2)-M17 cells
(ATCC, Manassas, VA, USA) was carried out as per
manufacturer’s guidelines (ATCC, USA). Cell lines
were cultured with growth medium (Dulbecco’s mod-
ified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 1% Pen-Strep;
growth medium was approximately 5–10 mL for
25 cm2) in culture flasks. Cells were checked daily by
a microscope (BX51, Olympus, Japan) and ensured
they were heathy and growing as expected during
incubation at 37◦C and 5% CO2 (incubator: Her-
acell Vios 160i, Thermo Scientific, US). The cells
were attached to the bottom of the flask, as round and
plump or elongated in shape. Cells grew until 70%
confluence.
2.1.3. Neurotoxicity of amyloid beta 42
determination
The neurotoxicity of amyloid beta 42 was first
assessed by treating the cells with 100 L treat-
ment medium (prepared as 5 mL 1% fetal calf serum
Table 1
Amyloid beta concentrations and culture time
Amyloid beta Incubation








Protein concentration of sample without amyloid beta
Sample Sample Cell lysate Cell medium
treatment concentration protein protein
(g/mL) concentration concentration
(g/mL) (g/mL)




2 GBP 0.9 17.52 ± 0.06a 6.26 ± 0.05a
3 GBP 1.2 17.16 ± 0.17b 6.52 ± 0.05b
4 GBP 1.5 17.12 ± 0.08b 6.42 ± 0.02ab
Letters such as a, b and c are the superscripts of protein concen-
trations based on mean ± SD. Different letters indicate the protein
concentrations of each column are significantly different (p < 0.05).
(FCS) + 45 mL DMEM/F-12 (Dulbecco’s Modified
Eagle Medium/Ham’s F-12) supplemented with dif-
ferent concentrations of amyloid beta 42 (20, 30 and
40 M) per well as per Table 1. Then the 96-well
plate was incubated (incubator: Heracell Vios 160i,
Thermo Scientific, US) at 37◦C and 5% CO2 for 48 h
and 72 h respectively. After incubation, 20 L MTS
solution was pipetted into each well and the 96-well
plate was immediately wrapped with aluminium foil
and placed into the incubator again for 4 h until pur-
ple precipitate was visible. The absorbance of each
well at 570 nm was recorded by a Multimode Plate
Reader (Enspire, US).
2.1.4. Pre-screening of GBP
To pre-screen GBP, wells contained different con-
centrations (0.3–1.8 g/mL) of GBP with 100 L
treatment medium per well were incubated (incuba-
tor: Heracell Vios 160i, Thermo Scientific, US) at
37◦C and 5% CO2 for 48 h. After incubation, 20 L
MTS solution was pipetted into each well and the
96-well plate was immediately wrapped with alu-
minium foil and placed into the incubator again for 4 h
until purple precipitate was visible. The absorbance
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of each well at 570 nm was recorded by a Multimode
Plate Reader (Enspire, US).
2.1.5. MTS assay for cell viability
Cells were treated with 100 L treatment medium
and 20 M amyloid beta 42 at different concentra-
tions (0.6, 0.9, 1.2, 1.5 and 1.8 g/mL) of GBP. The
96-well plate was incubated (incubator: Heracell Vios
160i, Thermo Scientific, US) at 37◦C and 5% CO2 for
48 h, followed by adding 20 L MTS solution into
each well. Then the 96-well was wrapped with alu-
minium foil and incubated again for 4 h (at 37◦C and
5% CO2). Cell viability was calculated based on the
absorbance which was recorded by a Multimode Plate
Reader (Enspire, US) at 570 nm using Equation 1.
N =
At − Ab
Ac − Ab × 1.2 × 10
4 (1)
Where:
N = number of cells,
At = absorbance of sample solution (sample solu-
tion + treatment media + cells + amyloid beta),
Ab = absorbance of the blank (treatment media
only),
Ac = absorbance of the control (cells + treatment
media) which was considered 100% viability,
1.2 × 104= number of cells in control.
2.2. Bicinchoninic acid (BCA) assay
The BCA protein assay is a colorimetric detec-
tion and used for quantification of total protein.
Carefully pipetted 100 L blank (1 × PBS), 100 L
protein assay standard and 100 L diluted cell super-
natants (cell supernatants were diluted in 1 × PBS at
a ratio of 1:100, v/v) onto each well of 96-well plate.
Then 100 L BCA mix (5 mL reagent A, 4.8 mL
reagent B and 0.2 mL reagent C) was added into each
well. The 96-well plate was incubated at 69◦C for
20 mins (incubator: UL30, MEMMERT, Germany).
Absorbance was measured at 550 nm. The reduc-
tion of amyloid beta concentration was calculated
between protein concentration of control and sam-
ple with amyloid beta and without amyloid beta as
per Equation 2.
CR = (CA − CB) − (CS − CW) (2)
Where:
CR = reduction of amyloid beta concentration,
CA = protein concentration of amyloid beta only,
CB = protein concentration of blank,
CS = protein concentration of sample with amyloid
beta,
CW = protein concentration of sample but no amy-
loid beta,
CA − CB = amyloid beta concentration of control.
2.3. Western blot analysis
Western blot analysis was conducted as per proto-
cols developed by the manufacturer (Bio-Rad, US).
2.3.1. Preparation of cell lysate and media
A density of 1.2 × 105 cells per well was trans-
ferred into the 12-well plate. Then 800 L treatment
medium (prepared as 5 mL 1% FCS + 45 mL DMEM/
F12 (1:1)) and 200 L amyloid beta (100 mM) were
pipetted into each well.
Then 0.9, 1.2 and 1.5 g/mL (these concentra-
tions were selected according to MTS assay results)
of GBP solution was pipetted respectively into each
well. The 12-well plate was immediately placed into
an incubator (Heracell Vios 160i, Thermo Scientific,
US) for 24 h (condition: 37◦C with 5% CO2). Then
the plate was removed from the incubator and placed
on ice. Cells were washed using 800 L ice-cold
1 × Hanks’ Balanced Salt Solution (HBSS) after
collecting the treatment medium. Then 33 L ice-
cold lysis buffer (formulation: 10% 10 × phosphate
buffered saline (PBS), 10% sodium dodecyl sulfate
(SDS):Trix, 4% protease inhibitor and 76% purified
water) was added into each well for 1-2 min after
removal of HBSS. Cell lysate was then collected
into a pre-cooled microcentrifuge tube using a cell
scraper. Both cell lysate and cell medium were placed
on ice for further analysis after a 10 min sonication
(ultrasonic cleaner: 250HD, SONICLEAN, Japan).
2.3.2. Loading and running the gel
Before starting Western blot analysis, the volume
of cell lysate or cell medium pipetted into each tube






V = volume of cell supernatants (L),
C = protein concentration (L/mL).
Then carefully pipetted required volume of cell
lysate or cell medium, 18.80 L 4 × Sample Buffer,
7.50 L 10 × Reducing Agent into a new tube and
topped up to 75 L with purified water. The tube went
through vortex for seconds (vortexer: N12504, VELP,
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Italy), sonication for 10 mins (ultrasonic cleaner:
250HD, SONICLEAN, Japan), and incubation for
5 mins at 95◦C (dry block heater: DBH30D, Ratek,
Australia).
Set up the gel tank and power pack including the gel
(Bio-Rad TGX stain free 4–15% gel). Then poured
the running buffer (1 × 2- (N-morpholino) ethane-
sulfonic acid (MES) SDS Running Buffer) into the
gap between the cassette and gel (ensured no running
buffer was leaking from the tank). Carefully removed
the comb of the gel once the wells were immerged.
Immediately ran the gel at 110 V after loading 7 L
molecular-weight marker and 25 L protein sample
solution into each cassette well respectively. Stopped
the gel-running once the dye front met gel foot. Then
placed the gel carefully onto a tray which was pre-
filled with running buffer since the gel was removed
from the cassette.
Placed the gel on nitrocellulose membrane accord-
ing to the manufacturer’s guidelines (Transfer Kit
1704270, Bio-Rad, US) and immediately transferred
it to the Transfer System (Trans-Blot Turbo System,
Bio-Rad, US) for 7 min run in which the protein was
transferred to the membrane during this process. Then
removed gel from the membrane and placed it onto
a tray with 1 × tris-buffered saline (TBS). Cut the
membrane by a knife for a better shape in a glass
slab.
2.3.3. Antibody staining
The membranes were washed 3 × 5 min using
25 mL 1 × TBS (pH adjusted to 7.4) in a lid
(approximately 15 cm × 15 cm) on the rocking plat-
form, followed by being boiled for 40 seconds in
pre-microwaved 25 mL 1 × PBS (microwave oven:
MS40J5133BT, Samsung, Korea). The membranes
were rinsed twice by 1 × PBS until it cooled down.
The membranes were blocked in 25 mL 1 × TBS with
5% skim milk for 1 h and then incubated by 25 mL
1 × TBST (1 × TBS added with 0.1% Tween 20) with
0.5% skim milk plus 10 L primary antibody WO2
(Sigma-Aldrich, US) (1:2500 dilution) on a rocking
platform overnight in a 4◦C cold room. Then the
membranes were washed by 25 mL 1 × TBST for
3 × 10 mins and incubated with 5 L secondary anti-
body anti-mouse HRP (Thermofisher, US) in TBST
with 0.5% skim (1:5000 dilution) milk for 1 h at room
temperature. The membranes were further washed in
1 × TBST for 3 × 10 mins followed by being rinsed
in 1 × TBS for 2–3 mins. Then the membranes were
incubated for 2 mins with ECL reagent (a mixture
of detection reagent 1 and 2 at 1:1 from the ECL
Western blot Detection Reagents Kid, GE Healthcare
UK, 50 mL ECL reagent for 4 membranes) and shake
vigorously. Then exposed membranes were scanned
using chemiluminescence imaging system (Fusion
FX Spectra, Vilber Lourmat). The immune-reactive
bands were quantified through Bio-Rad Quantity One
1-D analysis software. Amyloid beta ratio based on
density was calculated to see the effect of GBP on the
reduction of amyloid beta as per Equation 4.
Relative density (%) of amyloid beta
= DS − DB
DA − DB × 100% (4)
Where:
DS = density of sample with amyloid beta,
DA = density of amyloid beta only,
DB = density of blank (no amyloid beta and
sample).
2.4. Enzyme-linked immunosorbent assay
(ELISA)
ELISA was performed at 450 nm within 30 min
after adding the Stop Solution as per manufacturer’s
guidelines (Thermo Scientific, US). The standard
curve was automatically drawn by the curve-fitting
software (BMG OPTIMA Windows) based on read-
ings of unknown samples and control concentrations
through the microplate reader (BMG FLUOstar
Optima, Germany). Dilution factor was considered
for calculation of amyloid beta 42 concentration.
2.5. AFM
AFM was conducted as per method described by
Stine et al. [15]. Carefully pipetted 3 L of 1 M HCl
onto the mica surface and ensure it covered the full
surface, followed by an incubation for 30 seconds
at room temperature. Used two drops of ultrapure
water from syringe filter (0.02 m) at 45◦ angle to
wash the mica surface. Then sample solution was
delivered onto the mica surface in full via a syringe
and followed by a 3 min room temperature incuba-
tion. Rinsed the mica surface with three drops of
water by the syringe filter and followed by blow dry
using several gentle pulses of compressed air. The
sample solution was analysed for AFM once it was
completely dried after room temperature incubation.
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Fig. 1. Cell number at different amyloid beta concentrations. Letters such as a, b, c and d are the superscripts of cell numbers based on
mean ± SD. Different letters indicate the cell numbers of each column are significantly different (p < 0.05).
2.6. Sample size
This study was carried out with and without amy-
loid beta for each concentration of GBP. Based on our
previous in vitro work using short chain fatty acids, 6
cell culture plates (24 well) per group were used for
statistical significance to be achieved. Total sample
size was determined to be 32 for this investigation
assuming a failure rate of 5%.
2.7. Statistical analysis
All analyses were carried out in triplicate with
data were presented as mean/standard deviation (SD).
Statistical tests were conducted using the STATA
statistical analysis software program version 12
(Stata Corp LLC, US). One-way analysis of variance
(ANOVA) was used to determine the effect of GB
on amyloid beta through different cell culture tech-
niques. The p value of less than 0.05 (p < 0.05) was
considered for significant difference.
3. Results
3.1. Effect of amyloid beta on cell viability
MTS assay results showed that compared with
untreated cells, cell viability was significantly inhib-
ited in cells treated with amyloid beta 42 alone,
while 50 % or more of cell viability was significantly
decreased after treatment with 20 M (p < 0.01) or
30 M but not for 10 M (Fig. 1). Although decrease
of cells were observed at 48 h and 72 h, 50% reduction
was observed at 72 h when amyloid bate concentra-
tion was 20 M. Therefore, based on MTS assay, the
treatment with 20 M amyloid beta 42 for 72 h was
used in subsequent experiment [16].
Fig. 2. Effect of GBP concentrations on cell viability. Letters such
as a, b, c and d are the superscripts of cell numbers based on
Mean ± SD. Different letters indicate the cell numbers of each
column are significantly different (p < 0.05).
3.2. Effect of GBP on cell viability
GBP inhibited amyloid beta induced cell death in
a dose-dependent manner as per Fig. 2. Cell viability
was significantly (p < 0.01) increased with increased
GBP concentration from 0.6 to 1.2 g/mL, whilst
there was a significant decrease of cell viability in the
range of 1.2–1.8 g/mL of GBP. The highest cell via-
bility (105%) appeared when GBP was 1.2 g/mL.
As shown in Fig. 3, cells appeared more elongated
when treated with GB.
3.3. Bicinchoninic acid (BCA) assay
The resulted protein concentration of sample based
on cell lysate was dependent on the GB concen-
tration. For example, protein concentrations of cells
treated with three different GB concentrations were
24.67, 24.22 and 24.10 g/mL respectively (Table 3).
Results implies that higher concentration of GBP
could decrease the concentration of amyloid beta in
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Fig. 3. Cell morphology of GBP treated with amyloid beta induced cells at 72 h culture. (a) Amyloid beta only (20 M); (b) control (only
cells without amyloid beta and GBP); (c) cells treated with GBP at 1.2 g/mL.
Table 3
Protein concentration of sample with amyloid beta
Sample Sample Cell lysate Cell medium
treatment concentration protein protein
(g/mL) concentration concentration
(g/mL) (g/mL)




2 GBP 0.9 24.67 ± 0.11a 9.56 ± 0.09a
3 GBP 1.2 24.22 ± 0.17b 9.58 ± 0.02a
4 GBP 1.5 24.10 ± 0.07b 9.44 ± 0.00a
Letters such as a, b and c are the superscripts of protein con-
centrations based on mean ± SD. Different letters indicate the
protein concentrations of each column are significantly different
(p < 0.05).
Table 4
Reduced amyloid beta concentration
Sample Sample Reduced Reduced
treatment concentration amyloid beta amyloid beta
(g/mL) concentration concentration
in cell lysate in cell medium
(g/mL) (g/mL)
1 GBP 0.9 0.80 ± 0.06b 2.89 ± 0.14b
2 GBP 1.2 0.89 ± 0.00ba 3.14 ± 0.03a
3 GBP 1.5 0.98 ± 0.01a 3.18 ± 0.02a
Letters such as a, b and c are the superscripts of reduced amy-
loid beta concentrations based on mean ± SD. Different letters
indicate reduced amyloid beta concentrations of each column are
significantly different (p < 0.05).
cells (Table 3). Proteins comes from cell itself and
added amyloid beta. In the light of results, GB had
reduced the concentration of protein in cell lysate by
22.5%. The highest protein concentration reduction
(0.98 g/mL) was reported at the concentration of
1.5 g/mL of GBP (Table 4).
Table 5
Results of western blot (density)
Sample Sample Amyloid beta Amyloid beta
treatment concentration density (104) density (104)
(g/mL) in cell lysate in cell medium
Amyloid beta N.A. 4.08 ± 0.01a 3.19 ± 0.01a
(100 mM) only
Blank N.A. 0.10 ± 0.00d 0.10 ± 0.00d
GBP 0.9 3.40 ± 0.04b 1.70 ± 0.02b
GBP 1.2 3.40 ± 0.04b 1.67 ± 0.05b
GBP 1.5 3.17 ± 0.04c 1.38 ± 0.03c
Letters such as a, b, c and d are the superscripts of amyloid beta den-
sities based on mean ± SD. Different letters indicate the amyloid
beta density of each column are significantly different (p < 0.05).
3.4. Western blot analysis
The density of amyloid beta from Western blot
is shown in Table 5. Cells treated with GBP at
1.5 g/mL showed the lowest amyloid beta den-
sity (3.17 × 104) in cell lysate while GBP was at
1.5 g/mL in cell medium indicated the highest
amyloid beta inhibition effect (amyloid beta den-
sity was 1.38 × 104). Cell lysate and cell medium
at 1.5 g/mL GBP showed the lowest amyloid beta
ratios (relative densities) indicating it was the most
effective concentration of GB against amyloid beta
(Fig. 4). Their blots in both cell lysate and cell
medium are shown in Fig. 5.
3.5. ELISA
Each sample was diluted at 1/3, 1/10, 1/100,
1/1000 and 1/10000 to ensure the unknown sam-
ple’s absorbance fell into the range of the standard
curve. The cell lysates at 0.9, 1.2 and 1.5 g/mL
GBP concentrations were selected for ELISA which
was based on MTS assay and Western blot analysis
results. When the concentration of GB was increased,
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the concentration of amyloid beta was decreased sig-
nificantly (p < 0.01). The amyloid beta concentration
at 0.9, 1.2 and 1.5 g/mL of GBP was 9199, 8821 and
8499 pg/mL respectively while that in control (amy-
loid beta only) was 10189 pg/mL (Fig. 6). Therefore,
GBP at 1.5 g/mL was the concentration with the
highest effect on amyloid beta reduction (17%) in
amyloid beta-induced neuronal cells compared to the
control (Fig. 6).
3.6. AFM
AFM was applied to estimate the approximate
molecular size distributions of amyloid beta (1–42)
oligomers after the treatment. The effect of GBP
concentration on amyloid beta is shown in Fig. 7.
The effect was dose dependent and lower aggrega-
tion or lower number of molecules were observed
with increased GBP concentration. Size of the oligo-
mers were reduced when treated with higher con-
centrations. For example, number and size of
oligomers were reduced while GBP concentration
was increased. There were some oligomeric amyloid
beta that could be observed when GBP was at 0.9 g/
mL (Fig. 7 (a)). When GBP concentration was in-
creased, amyloid beta was further inhibited as only
Fig. 4. Amyloid beta ratios at different GBP concentrations from
Western blot. Letters such as a and b are the superscripts of
amyloid beta concentration ratios based on mean ± SD. Different
letters indicate amyloid beta concentrations of the same-coloured
columns are significantly different (p < 0.05).
a few small (in height) amyloid beta oligomers were
identified in Fig. 7 (b) and (c).
The average particle diameters for the oligomeric
assemblies were 35 and 30 nm for amyloid beta only
(20 M) and that with GBP at 0.9 g/mL respectively
(Table 6). The GBP at 1.5 g/mL showed the smallest
diameter (25 nm) with the lowest particle number [45]
which indicated the strongest inhibitive effect against
amyloid beta.
4. Discussion
Amyloid beta peptide is produced through the pro-
teolytic cleavage from an integral transmembrane
domain of the amyloid protein precursor (APP)
by - and -secretases. After cleavage, amyloid
beta peptide becomes either toxic soluble/diffusible
oligomers (amyloid-beta) or relatively inert fib-
rillary amyloid polymers within the extracellular
interstitial compartments as plaques and perivascu-
lar deposits [17, 18]. In AD brain, it contains an
average 6.5 ± 5.0 mg amyloid beta compared to a
1.7 ± 2.3 mg in healthy brain [2]. The estimated time
frame of amyloid beta accumulation from threshold
to onset of dementia is 19.2 years, and the rate of
Fig. 6. The effect of GBP concentration on amyloid beta from
ELISA. Letters such as a, b and c are the superscripts of amyloid
beta concentrations based on mean ± SD. Different letters indi-
cate amyloid beta concentrations of the columns are significantly
different (p < 0.05).
Fig. 5. Effect of GBP on amyloid beta blot. (1) Amyloid beta only; (2) GBP at 0.9 g/mL; (3) GBP at 1.2 g/mL; (4) GBP at 1.5 g/mL.
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Fig. 7. Effect of GBP at different concentrations on amyloid beta. Representative AFM images of adsorbed 20 M amyloid beta (1–42)
oligomers prepared by HFIP protocol (Mica surfaces (3 × 3 m) were visualized after 24 h incubation with preparations (images in 3 × 3 m,
24 h incubation).
Table 6
Comparison of particle number and diameter of amyloid beta under
AFM
Sample Concentration Average Number of
(g/mL) particle size particles
(diameter, nm) (in 3 × 3 m)
Amyloid beta N.A. 35 69
only (20 M)
GBP 0.9 30 57
GBP 1.2 27 50
GBP 1.5 25 45
Averages were calculated using three different images from three
trials.
amyloid beta accumulation in brain is 28 ± 27 ng/h
[19].
Several studies have revealed that amyloid beta
toxic properties in neurons are mediated by differ-
ent mechanisms, like oxidative stress, mitochondrial
diffusion, alterations in membrane permeability,
inflammation and synaptic dysfunction [20–22]. On
the other hand, the deposition of amyloid beta is con-
sidered as a major driving force in the initial stages
of AD. Therefore, reduction of amyloid beta toxicity
in cells is important when identifying a therapeutic
strategy for AD.
GB is a novel ingredient which has attracted a
great deal of attention due to its high biological
activities and health benefits. GB is rich in antiox-
idants such as phenolic acids and flavonoids. In
addition, the polysaccharides in GB have various
important biological activities, such as antioxida-
tion, immunomodulation, and neuroprotection [11,
14, 23]. In the neurological area, the extract or fruit
or powder of GB has been shown to have effects on
the brain and neuronal function through mechanisms
independent of its anti-oxidative effects. Although
the underlining mechanism of neuroprotection of GB
is not yet conclusive, the studies have shown that
GB can exhibit protective effects against neurotox-
icity by upregulating Nrf2/HO-1 signalling, reverse
the H2O2-induced reactive oxygen species (ROS)
levels, increase in caspase-3 and -9 activity and
decrease in mitochondrial membrane potential [18].
GB also has demonstrated the signs of decreasing the
infarct size, hemispheric swelling and water content
in male mice after consumption of GB polysaccha-
rides for 7 days [24]. Amyloid beta peptides in brain
activate c-Jun N-terminal kinase (JNK) by phos-
phorylation [25]. However, treatment with GB had
shown a marked reduction of phosphorylation of
JNK-1 [Thr183/Tyr185] and its substrates c-Jun-I
[Ser 73] and c-Jun-II [Ser 63] [26]. Recently, double-
blind randomized control study with young healthy
participants has shown the evidences of improved
neurological performance after consumption of GB
for 14 days [27]. These studies support the anti-aging
properties as well as the neurological effects found in
the present study.
The presence of low physiological concentrations
of amyloid beta in brain (picomoles) plays impor-
tant roles in the facilitation of synaptic plasticity,
memory and learning, whereas the accumulation of
high concentrations of amyloid beta (nanomoles or
micromoles) results in loss of synaptic function as
shown in the AD [28]. As shown in our previous
work, reduction of amyloid beta even in picomoles
may contribute to higher scores in memory improve-
ment in AD patients [29]. The present study clearly
demonstrated that GB significantly reduced the cell
death by enhancing the cell viability of amyloid beta
treated cells (20 micromoles) in the concentration
of 0.6 to 1.2 g/mL. The mechanism by which GB
exerts the neuroprotection may be its strong antiox-
idative and anti-aging properties. GB could protect
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DNA, lipids and proteins from free radicals relat-
ing to damage and alleviate oxidative stress [14]. For
example, GB polysaccharides could increase H2O2-
induced cell viability and reduce CoCl2-treated brain
tissue apoptosis [30]. The consumption of GB at rec-
ommended quantity (5–12 g) could also reduce DNA
damage and maintain cell functions appropriately
[31]. However, our study identified that concentra-
tion of 1.2–1.8 g/mL GBP led to decrease in cell
viability (Fig. 2). Higher concentration of GBP pro-
vides high sugar content which could cause apoptosis
of the cells and the formation of reactive oxygen
species (ROS) [32]. Alternatively, the reduction in
cell death by GB at the tested concentrations may be
explained as a consequence of the reduction in amy-
loid beta concentrations which occurred at the same
concentrations (Table 4, Fig. 4 and Fig. 5)
Our work further proved the capacity of GB to
reduce the quantity of amyloid beta in neuronal
cells. Simultaneously, more elongated cells that were
treated with GB indicated GB neuroprotective effect
against amyloid beta [33]. This was further evident
by the results of the Western blot, AFM and ELISA.
The Western blot analysis has confirmed the presence
of lower density of amyloid beta in treated cells than
controlled ones. Amyloid beta density was reduced
by 20% at the concertation of 1.5 g/mL GBP. West-
ern blot can separate smaller oligomeric forms of
amyloid beta as well as monomeric amyloid beta but
not the fibrillar aggregates of amyloid beta due to
its size and the mass [34–36]. The results of ELISA
which quantify the total level of amyloid beta includ-
ing fibrils further demonstrated that GB could reduce
amyloid beta concentration in neuronal cells which
was consistent to the outcomes of MTS assay and
Western blot [37, 38]. GB potent cytoprotective effect
may have inhibited amyloid beta which helped to
decrease amyloid beta concentration [33, 39].
Aggregation of amyloid beta is toxic to neurons
and may trigger apoptosis in AD [40]. The exposure
of neurons to amyloid beta deposits increased in Par-
4, Bax, and p53, and the release of cytochrome c result
in caspase-3 activation then apoptosis [41]. There-
fore, it is also plausible that GB may also reduce
amyloid beta-induced cell death by inhibiting the
aggregation of amyloid beta. The results of AFM
showed the smaller particles of amyloid beta after
the treatment indicating the inhibition of aggregation
of oligomeric amyloid beta. The similar results were
obtained with curcumin [42]. This may be attributed
to reduction of ROS formed by amyloid beta since
GB is a strong antioxidant.
In conclusion, MTS, BCA assay, Western blot
analysis and ELISA have indicated that GBP at the
concertation of 1.5 g/mL could significantly impact
on the AD amyloidogenesis process through reduc-
tion of amyloid beta. The effect of GBP against
amyloid beta aggregation is further supported by
AFM from imaging perspective. This indicates that
GB could significantly affect the amyloidogenesis
process of AD reducing its risk. GBP at 1.5 g/mL
is the most effective concentration on amyloid beta
reduction in amyloid beta-induced neuronal cells.
However, permeability of GB to blood-brain barrier
remained to be elusive to understand its effect in
humans.
Acknowledgments
The authors thank Western Sydney University and
CSIRO for their financial support. The present study
was mainly conducted at the Australian Alzheimer’s
Research Foundation, Ralph and Patricia Sarich Neu-
roscience Research Institute. The authors thank their
support.
Funding
This work was supported by Western Sydney
University PhD Scholarship and CSIRO Top-up
Scholarship.
Conflict of interest
The authors have no conflict of interest to report.
References
[1] Morris J, Galvin JE, Holtzman DM. Handbook of Dementing
Illnesses. Boca Raton: CRC Press 2006.
[2] Roberts BR, Lind M, Wagen AZ, Rembach A, Frugier T, Li Q,
et al. Biochemically-defined pools of amyloid- in sporadic
Alzheimer’s disease: correlation with amyloid PET. Brain.
2017;140(5):1486-98.
[3] Carter J, Lippa CF. Beta-amyloid, neuronal death and
Alzheimer’s disease. Current Molecular Medicine. 2002;
1(6):733-7.
[4] Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer’s
disease. Current Neurology and Neuroscience Reports.
2007;7(5):366-72.
[5] Amagase H, Farnsworth NR. A review of botanical char-
acteristics, phytochemistry, clinical relevance in efficacy and
W.M.A.D.B. Fernando et al. / Effect of goji berry on the formation of extracellular senile plaques of Alzheimer’s disease 115
safety of Lycium barbarum fruit (Goji). Food Research Inter-
national. 2011;44(7):1702-17.
[6] Zhang J. Antioxidant Properties of Goji Berries. Detroit:
Wayne State University; 2013.
[7] Skenderidis P, Lampakis D, Giavasis I, Leontopoulos S,
Petrotos K, Hadjichristodoulou C, et al. Chemical Proper-
ties, Fatty-Acid Composition, and Antioxidant Activity of
Goji Berry (Lycium barbarum L. and Lycium chinense Mill.)
Fruits. Antioxidants. 2019;8(60):1-13.
[8] Soneji JR, Nageswara-Rao M. Breeding and Health Benefits
of Fruit and Nut Crops. Chen J, C.T. C, X. W, editors. London:
IntechOpen Limited; 2018.
[9] Peng Y, Ma C, Li Y, Leung K, Jiang Z, Zhao Z. Quan-
tification of zeaxanthin dipalmitate and total carotenoids in
Lycium fruits (Fructus lycii). Plant Foods For Human Nutri-
tion. 2005;60(4):161- 4.
[10] Shan X, Zhou J, Ma T, Chai Q. Lycium barbarum
Polysaccharides Reduce Exercise-Induced Oxidative. Inter-
national Journal of Molecular Sciences. 2011;12(2):
1081-8.
[11] Shi Z, Zhu L, Li T, Tang X, Xiang Y, Han X, et al. Neuro-
protective Mechanisms of Lycium barbarum Polysaccharides
Against Ischemic Insults by Regulating NR2B and NR2A
Containing NMDA Receptor Signaling Pathways. Frontiers
in Cellular Neuroscience. 2017;11:288.
[12] Miwa M, Tsuboi M, Noguchi Y, Enokishima A, Nabeshima
T, Hiramatsu M. Effects of betaine on lipopolysaccharide-
induced memory impairment in mice and the involvement of
GABA transporter 2. Journal Of Neuroinflammation. 2011;
8:153.
[13] Shah T, Bule M, Niaz K. Goji Berry Lycium barbarum–
(superfood). Nonvitamin and Nonmineral Nutritional Sup-
plements 1st Edition. Amsterdam: Academic Press Elsevier
Publisher; 2018.
[14] Ma ZF, Zhang H, Teh SS, Wang CW, Zhang Y, Hayford F, et
al. Goji Berries as a Potential Natural Antioxidant Medicine:
An Insight into Their Molecular Mechanisms of Action.
Oxidative Medicine and Cellular Longevity. 2019;2019:
2437397.
[15] Stine WB, Jungbauer L, Yu C, Ladu MJ. Preparing synthetic
A in different aggregation states. Methods in Molecular
Biology. 2011;670:13-32.
[16] Liu Y, Jia M, Xie Z, Liu X, Yang H, Zheng X, et al. Arrestins
Contribute to Amyloid Beta-induced Cell Death via Modu-
lation of Autophagy and The 7nAch Receptor in SH-SY5Y
Cells. Scientific Reports. 2017;7:3446.
[17] Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed
R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived
from A1-42 are potent central nervous system neurotoxins.
Proceedings of The National Academy of Sciences of The
United States of America. 1998;95(11):6448-53.
[18] McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ,
Beyreuther K, et al. Soluble pool of Abeta amyloid as a
determinant of severity of neurodegeneration in Alzheimer’s
disease. Annals of Neurology. 1999;46(6):860-6.
[19] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis
KA, Salvado O, et al. Amyloid  deposition, neurodegenera-
tion, and cognitive decline in sporadic Alzheimer’s disease: a
prospective cohort study. The Lancet Neurology. 2013;12(4):
357-67.
[20] Forner S, Baglietto-Vargas D, Martini AC, Trujillo-Estrada
L, LaFerla FM. Synaptic Impairment in Alzheimer’s Dis-
ease: A Dysregulated Symphony. Trends in Neurosciences.
2016;40(6).
[21] Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G.
Mitochondrial Dysfunction Is A Trigger of Alzheimer’s Dis-
ease Pathophysiology. Biochimica et Biophysica Acta. 2010;
1802(1):2-10.
[22] Onyango IG, Dennis J, Shaharyah MK. Mitochondrial Dys-
function in Alzheimer’s Disease and the Rationale for Bioen-
ergetics Based Therapies. Aging and Disease. 2016;7(2):
201-14.
[23] He N, Yang X, Jiao Y, Tian L, Zhao Y. Characterisation
of Antioxidant and Antiproliferative Acidic Polysaccharides
from Chinese Wolfberry Fruits. Food Chemistry. 2012;
133(3):978-89.
[24] Yang D, Li S, Yeung C, Chang RC, So K, Wong D,
et al. Lycium barbarum Extracts Protect the Brain from
Blood-Brain Barrier Disruption and Cerebral Edema in
Experimental Stroke. PLoS One. 2012;7(3):e33596.
[25] Fogarty MP, Downer EJ, Campbell V. A role for c-Jun N-
terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-
mediated stabilization of protein p53 and induction of the
apoptotic cascade in cultured cortical neurons. Biochemical
Journal. 2003;371(Pt 3):789-98.
[26] Li L, Feng Z, Porter AG. JNK-dependent Phosphorylation of
c-Jun on Serine 63 Mediates Nitric Oxide-induced Apoptosis
of Neuroblastoma Cells. The American Society for Biochem-
istry and Molecular Biology. 2004;279(6):4058-65.
[27] Amagase H, Nance DM. A Randomized, Double-Blind,
Placebo-Controlled, Clinical Study of the General Effects
of a Standardized Lycium barbarum (Goji) Juice, GoChi ™.
The Journal of Alternative and Complementary Medicine.
2008;14(4):403-12.
[28] Cárdenas-Aguayo MdC, Silva-Lucero MdC, Cortes-Ortiz M,
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